BC007 is a novel autoantibody-neutralizing drug that targets G-protein-coupled receptor autoantibodies, potentially disrupting pathological neurological processes associated with Depersonalization-derealization disorder. By blocking these autoantibodies, BC007 may restore normal neurotransmitter signaling and reduce the dissociative symptoms characteristic of DPDR, offering a potential targeted therapeutic approach for this challenging psychiatric condition.